

# EMEA (Europe, Middle East and Africa) Immune Checkpoint Inhibitors Market Report 2017

<https://marketpublishers.com/r/E6E04877476PEN.html>

Date: October 2017

Pages: 112

Price: US\$ 4,000.00 (Single User License)

ID: E6E04877476PEN

## Abstracts

In this report, the EMEA Immune Checkpoint Inhibitors market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Immune Checkpoint Inhibitors for these regions, from 2012 to 2022 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Immune Checkpoint Inhibitors market competition by top manufacturers/players, with Immune Checkpoint Inhibitors sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

Bristol Myer Squibb

AstraZeneca

Merck & Co.

Roche / Genentech

Incyte Corporation

NewLink Genetics

ArGEN-X

Seattle Genetics

Pfizer

MacroGenics

Celldex Therapeutics

CureTech

Immutep

Innate Pharma

Sorrento Therapeutics

GlaxoSmithKline

GITR, Inc

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into

PD-1/PD-L1

CTLA-4

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Pcs), market share and

growth rate of Immune Checkpoint Inhibitors for each application, including

Lung Cancer

Colorectal Cancer

Breast Cancer

Prostate Cancer

Melanoma

Blood Cancer

Other

If you have any special requirements, please let us know and we will offer you the report as you want.

## Contents

### EMEA (Europe, Middle East and Africa) Immune Checkpoint Inhibitors Market Report 2017

#### **1 IMMUNE CHECKPOINT INHIBITORS OVERVIEW**

##### 1.1 Product Overview and Scope of Immune Checkpoint Inhibitors

##### 1.2 Classification of Immune Checkpoint Inhibitors

##### 1.2.1 EMEA Immune Checkpoint Inhibitors Market Size (Sales) Comparison by Type (2012-2022)

##### 1.2.2 EMEA Immune Checkpoint Inhibitors Market Size (Sales) Market Share by Type (Product Category) in 2016

##### 1.2.3 PD-1/PD-L1

##### 1.2.4 CTLA-4

##### 1.3 EMEA Immune Checkpoint Inhibitors Market by Application/End Users

##### 1.3.1 EMEA Immune Checkpoint Inhibitors Sales (Volume) and Market Share Comparison by Application (2012-2022)

##### 1.3.2 Lung Cancer

##### 1.3.3 Colorectal Cancer

##### 1.3.4 Breast Cancer

##### 1.3.5 Prostate Cancer

##### 1.3.6 Melanoma

##### 1.3.7 Blood Cancer

##### 1.3.8 Other

##### 1.4 EMEA Immune Checkpoint Inhibitors Market by Region

##### 1.4.1 EMEA Immune Checkpoint Inhibitors Market Size (Value) Comparison by Region (2012-2022)

##### 1.4.2 Europe Status and Prospect (2012-2022)

##### 1.4.3 Middle East Status and Prospect (2012-2022)

##### 1.4.4 Africa Status and Prospect (2012-2022)

##### 1.5 EMEA Market Size (Value and Volume) of Immune Checkpoint Inhibitors (2012-2022)

##### 1.5.1 EMEA Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2022)

##### 1.5.2 EMEA Immune Checkpoint Inhibitors Revenue and Growth Rate (2012-2022)

#### **2 EMEA IMMUNE CHECKPOINT INHIBITORS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION**

## 2.1 EMEA Immune Checkpoint Inhibitors Market Competition by Players/Manufacturers

2.1.1 EMEA Immune Checkpoint Inhibitors Sales Volume and Market Share of Major Players (2012-2017)

2.1.2 EMEA Immune Checkpoint Inhibitors Revenue and Share by Players (2012-2017)

2.1.3 EMEA Immune Checkpoint Inhibitors Sale Price by Players (2012-2017)

## 2.2 EMEA Immune Checkpoint Inhibitors (Volume and Value) by Type/Product Category

2.2.1 EMEA Immune Checkpoint Inhibitors Sales and Market Share by Type (2012-2017)

2.2.2 EMEA Immune Checkpoint Inhibitors Revenue and Market Share by Type (2012-2017)

2.2.3 EMEA Immune Checkpoint Inhibitors Sale Price by Type (2012-2017)

## 2.3 EMEA Immune Checkpoint Inhibitors (Volume) by Application

## 2.4 EMEA Immune Checkpoint Inhibitors (Volume and Value) by Region

2.4.1 EMEA Immune Checkpoint Inhibitors Sales and Market Share by Region (2012-2017)

2.4.2 EMEA Immune Checkpoint Inhibitors Revenue and Market Share by Region (2012-2017)

2.4.3 EMEA Immune Checkpoint Inhibitors Sales Price by Region (2012-2017)

# **3 EUROPE IMMUNE CHECKPOINT INHIBITORS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION**

## 3.1 Europe Immune Checkpoint Inhibitors Sales and Value (2012-2017)

3.1.1 Europe Immune Checkpoint Inhibitors Sales Volume and Growth Rate (2012-2017)

3.1.2 Europe Immune Checkpoint Inhibitors Revenue and Growth Rate (2012-2017)

## 3.2 Europe Immune Checkpoint Inhibitors Sales and Market Share by Type

## 3.3 Europe Immune Checkpoint Inhibitors Sales and Market Share by Application

## 3.4 Europe Immune Checkpoint Inhibitors Sales Volume and Value (Revenue) by Countries

3.4.1 Europe Immune Checkpoint Inhibitors Sales Volume by Countries (2012-2017)

3.4.2 Europe Immune Checkpoint Inhibitors Revenue by Countries (2012-2017)

3.4.3 Germany Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

3.4.4 France Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

3.4.5 UK Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

3.4.6 Russia Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

3.4.7 Italy Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

3.4.8 Benelux Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

#### **4 MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION**

4.1 Middle East Immune Checkpoint Inhibitors Sales and Value (2012-2017)

4.1.1 Middle East Immune Checkpoint Inhibitors Sales Volume and Growth Rate (2012-2017)

4.1.2 Middle East Immune Checkpoint Inhibitors Revenue and Growth Rate (2012-2017)

4.2 Middle East Immune Checkpoint Inhibitors Sales and Market Share by Type

4.3 Middle East Immune Checkpoint Inhibitors Sales and Market Share by Application

4.4 Middle East Immune Checkpoint Inhibitors Sales Volume and Value (Revenue) by Countries

4.4.1 Middle East Immune Checkpoint Inhibitors Sales Volume by Countries (2012-2017)

4.4.2 Middle East Immune Checkpoint Inhibitors Revenue by Countries (2012-2017)

4.4.3 Saudi Arabia Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

4.4.4 Israel Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

4.4.5 UAE Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

4.4.6 Iran Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

#### **5 AFRICA IMMUNE CHECKPOINT INHIBITORS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION**

5.1 Africa Immune Checkpoint Inhibitors Sales and Value (2012-2017)

5.1.1 Africa Immune Checkpoint Inhibitors Sales Volume and Growth Rate (2012-2017)

5.1.2 Africa Immune Checkpoint Inhibitors Revenue and Growth Rate (2012-2017)

5.2 Africa Immune Checkpoint Inhibitors Sales and Market Share by Type

5.3 Africa Immune Checkpoint Inhibitors Sales and Market Share by Application

5.4 Africa Immune Checkpoint Inhibitors Sales Volume and Value (Revenue) by Countries

5.4.1 Africa Immune Checkpoint Inhibitors Sales Volume by Countries (2012-2017)

5.4.2 Africa Immune Checkpoint Inhibitors Revenue by Countries (2012-2017)

5.4.3 South Africa Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

5.4.4 Nigeria Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

5.4.5 Egypt Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

5.4.6 Algeria Immune Checkpoint Inhibitors Sales and Growth Rate (2012-2017)

## **6 EMEA IMMUNE CHECKPOINT INHIBITORS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA**

### **6.1 Bristol Myer Squibb**

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

### **6.2 AstraZeneca**

6.2.1 Company Basic Information, Manufacturing Base and Competitors

6.2.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

### **6.3 Merck & Co.**

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Merck & Co. Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

### **6.4 Roche / Genentech**

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

### **6.5 Incyte Corporation**

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Incyte Corporation Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 NewLink Genetics

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 NewLink Genetics Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 ArGEN-X

6.7.1 Company Basic Information, Manufacturing Base and Competitors

6.7.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 ArGEN-X Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

6.8 Seattle Genetics

6.8.1 Company Basic Information, Manufacturing Base and Competitors

6.8.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Seattle Genetics Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview

6.9 Pfizer

6.9.1 Company Basic Information, Manufacturing Base and Competitors

6.9.2 Immune Checkpoint Inhibitors Product Type, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 Pfizer Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Main Business/Business Overview

6.10 MacroGenics

6.10.1 Company Basic Information, Manufacturing Base and Competitors



- 6.10.2 Immune Checkpoint Inhibitors Product Type, Application and Specification
  - 6.10.2.1 Product A
  - 6.10.2.2 Product B
- 6.10.3 MacroGenics Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2012-2017)
- 6.10.4 Main Business/Business Overview
- 6.11 Celldex Therapeutics
- 6.12 CureTech
- 6.13 Immutep
- 6.14 Innate Pharma
- 6.15 Sorrento Therapeutics
- 6.16 GlaxoSmithKline
- 6.17 GTR, Inc

## **7 IMMUNE CHECKPOINT INHIBITORS MANUFACTURING COST ANALYSIS**

- 7.1 Immune Checkpoint Inhibitors Key Raw Materials Analysis
  - 7.1.1 Key Raw Materials
  - 7.1.2 Price Trend of Key Raw Materials
  - 7.1.3 Key Suppliers of Raw Materials
  - 7.1.4 Market Concentration Rate of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
  - 7.2.1 Raw Materials
  - 7.2.2 Labor Cost
  - 7.2.3 Manufacturing Expenses
- 7.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors

## **8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

- 8.1 Immune Checkpoint Inhibitors Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Immune Checkpoint Inhibitors Major Manufacturers in 2016
- 8.4 Downstream Buyers

## **9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

- 9.1 Marketing Channel
  - 9.1.1 Direct Marketing

- 9.1.2 Indirect Marketing
- 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
  - 9.2.1 Pricing Strategy
  - 9.2.2 Brand Strategy
  - 9.2.3 Target Client
- 9.3 Distributors/Traders List

## **10 MARKET EFFECT FACTORS ANALYSIS**

- 10.1 Technology Progress/Risk
  - 10.1.1 Substitutes Threat
  - 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

## **11 EMEA IMMUNE CHECKPOINT INHIBITORS MARKET FORECAST (2017-2022)**

- 11.1 EMEA Immune Checkpoint Inhibitors Sales, Revenue and Price Forecast (2017-2022)
  - 11.1.1 EMEA Immune Checkpoint Inhibitors Sales and Growth Rate Forecast (2017-2022)
  - 11.1.2 EMEA Immune Checkpoint Inhibitors Revenue and Growth Rate Forecast (2017-2022)
  - 11.1.3 EMEA Immune Checkpoint Inhibitors Price and Trend Forecast (2017-2022)
- 11.2 EMEA Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.3 Europe Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.4 Middle East Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.5 Africa Immune Checkpoint Inhibitors Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.6 EMEA Immune Checkpoint Inhibitors Sales Forecast by Type (2017-2022)
- 11.7 EMEA Immune Checkpoint Inhibitors Sales Forecast by Application (2017-2022)

## **12 RESEARCH FINDINGS AND CONCLUSION**

## **13 APPENDIX**

## 13.1 Methodology/Research Approach

### 13.1.1 Research Programs/Design

### 13.1.2 Market Size Estimation

### 13.1.3 Market Breakdown and Data Triangulation

## 13.2 Data Source

### 13.2.1 Secondary Sources

### 13.2.2 Primary Sources

## 13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

## List Of Tables

### LIST OF TABLES AND FIGURES

- Figure Product Picture of Immune Checkpoint Inhibitors
- Figure EMEA Immune Checkpoint Inhibitors Sales Volume (K Pcs) by Type (2012-2022)
- Figure EMEA Immune Checkpoint Inhibitors Sales Volume Market Share by Type (Product Category) in 2016
- Figure PD-1/PD-L1 Product Picture
- Figure CTLA-4 Product Picture
- Figure EMEA Immune Checkpoint Inhibitors Sales Volume (K Pcs) by Application (2012-2022)
- Figure EMEA Sales Market Share of Immune Checkpoint Inhibitors by Application in 2016
- Figure Lung Cancer Examples
- Table Key Downstream Customer in Lung Cancer
- Figure Colorectal Cancer Examples
- Table Key Downstream Customer in Colorectal Cancer
- Figure Breast Cancer Examples
- Table Key Downstream Customer in Breast Cancer
- Figure Prostate Cancer Examples
- Table Key Downstream Customer in Prostate Cancer
- Figure Melanoma Examples
- Table Key Downstream Customer in Melanoma
- Figure Blood Cancer Examples
- Table Key Downstream Customer in Blood Cancer
- Figure Other Examples
- Table Key Downstream Customer in Other
- Figure EMEA Immune Checkpoint Inhibitors Market Size (Million USD) by Region (2012-2022)
- Figure Europe Immune Checkpoint Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Europe Immune Checkpoint Inhibitors Revenue (Million USD) Status and Forecast by Countries
- Figure Middle East Immune Checkpoint Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Middle East Immune Checkpoint Inhibitors Revenue (Million USD) Status and Forecast by Countries

Figure Africa Immune Checkpoint Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)

Figure Africa Immune Checkpoint Inhibitors Revenue (Million USD) Status and Forecast by Countries

Figure EMEA Immune Checkpoint Inhibitors Sales Volume and Growth Rate (2012-2022)

Figure EMEA Immune Checkpoint Inhibitors Revenue (Million USD) and Growth Rate (2012-2022)

Figure EMEA Immune Checkpoint Inhibitors Market Major Players Product Sales Volume (K Pcs) (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Sales Volume (K Pcs) of Major Players (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Sales Share by Players (2012-2017)

Figure 2016 Immune Checkpoint Inhibitors Sales Share by Players

Figure 2017 Immune Checkpoint Inhibitors Sales Share by Players

Figure EMEA Immune Checkpoint Inhibitors Market Major Players Product Revenue (Million USD) (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Revenue (Million USD) by Players (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Revenue Share by Players (2012-2017)

Table 2016 EMEA Immune Checkpoint Inhibitors Revenue Share by Players

Table 2017 EMEA Immune Checkpoint Inhibitors Revenue Share by Players

Table EMEA Immune Checkpoint Inhibitors Sale Price (USD/Pcs) by Players (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Sales (K Pcs) and Market Share by Type (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Sales Share by Type (2012-2017)

Figure Sales Market Share of Immune Checkpoint Inhibitors by Type (2012-2017)

Figure EMEA Immune Checkpoint Inhibitors Sales Market Share by Type (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Revenue (Million USD) and Market Share by Type (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Immune Checkpoint Inhibitors by Type in 2016

Table EMEA Immune Checkpoint Inhibitors Sale Price (USD/Pcs) by Type (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Sales (K Pcs) and Market Share by Application (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Sales Share by Application (2012-2017)

Figure Sales Market Share of Immune Checkpoint Inhibitors by Application (2012-2017)

Figure EMEA Immune Checkpoint Inhibitors Sales Market Share by Application in 2016

Table EMEA Immune Checkpoint Inhibitors Sales (K Pcs) and Market Share by Region (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Sales Share by Region (2012-2017)

Figure Sales Market Share of Immune Checkpoint Inhibitors by Region (2012-2017)

Figure EMEA Immune Checkpoint Inhibitors Sales Market Share in 2016

Table EMEA Immune Checkpoint Inhibitors Revenue (Million USD) and Market Share by Region (2012-2017)

Table EMEA Immune Checkpoint Inhibitors Revenue Share by Region (2012-2017)

Figure Revenue Market Share of Immune Checkpoint Inhibitors by Region (2012-2017)

Figure EMEA Immune Checkpoint Inhibitors Revenue Market Share Regions in 2016

Table EMEA Immune Checkpoint Inhibitors Sales Price (USD/Pcs) by Region (2012-2017)

Figure Europe Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Europe Immune Checkpoint Inhibitors Revenue and Growth Rate (2012-2017)

Table Europe Immune Checkpoint Inhibitors Sales (K Pcs) by Type (2012-2017)

Table Europe Immune Checkpoint Inhibitors Market Share by Type (2012-2017)

Figure Europe Immune Checkpoint Inhibitors Market Share by Type in 2016

Table Europe Immune Checkpoint Inhibitors Sales (K Pcs) by Application (2012-2017)

Table Europe Immune Checkpoint Inhibitors Market Share by Application (2012-2017)

Figure Europe Immune Checkpoint Inhibitors Market Share by Application in 2016

Table Europe Immune Checkpoint Inhibitors Sales (K Pcs) by Countries (2012-2017)

Table Europe Immune Checkpoint Inhibitors Sales Market Share by Countries (2012-2017)

Figure Europe Immune Checkpoint Inhibitors Sales Market Share by Countries (2012-2017)

Figure Europe Immune Checkpoint Inhibitors Sales Market Share by Countries in 2016

Table Europe Immune Checkpoint Inhibitors Revenue (Million USD) by Countries (2012-2017)

Table Europe Immune Checkpoint Inhibitors Revenue Market Share by Countries (2012-2017)

Figure Europe Immune Checkpoint Inhibitors Revenue Market Share by Countries (2012-2017)

Figure Europe Immune Checkpoint Inhibitors Revenue Market Share by Countries in 2016

Figure Germany Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure France Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure UK Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Russia Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Italy Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Benelux Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Middle East Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Middle East Immune Checkpoint Inhibitors Revenue (Million USD) and Growth Rate (2012-2017)

Table Middle East Immune Checkpoint Inhibitors Sales (K Pcs) by Type (2012-2017)

Table Middle East Immune Checkpoint Inhibitors Market Share by Type (2012-2017)

Figure Middle East Immune Checkpoint Inhibitors Market Share by Type (2012-2017)

Table Middle East Immune Checkpoint Inhibitors Sales (K Pcs) by Applications (2012-2017)

Table Middle East Immune Checkpoint Inhibitors Market Share by Applications (2012-2017)

Figure Middle East Immune Checkpoint Inhibitors Sales Market Share by Application in 2016

Table Middle East Immune Checkpoint Inhibitors Sales Volume (K Pcs) by Countries (2012-2017)

Table Middle East Immune Checkpoint Inhibitors Sales Volume Market Share by Countries (2012-2017)

Figure Middle East Immune Checkpoint Inhibitors Sales Volume Market Share by Countries in 2016

Table Middle East Immune Checkpoint Inhibitors Revenue (Million USD) by Countries (2012-2017)

Table Middle East Immune Checkpoint Inhibitors Revenue Market Share by Countries (2012-2017)

Figure Middle East Immune Checkpoint Inhibitors Revenue Market Share by Countries (2012-2017)

Figure Middle East Immune Checkpoint Inhibitors Revenue Market Share by Countries in 2016

Figure Saudi Arabia Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Israel Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure UAE Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Iran Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Africa Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate



(2012-2017)

Figure Africa Immune Checkpoint Inhibitors Revenue (Million USD) and Growth Rate (2012-2017)

Table Africa Immune Checkpoint Inhibitors Sales (K Pcs) by Type (2012-2017)

Table Africa Immune Checkpoint Inhibitors Sales Market Share by Type (2012-2017)

Figure Africa Immune Checkpoint Inhibitors Sales Market Share by Type (2012-2017)

Figure Africa Immune Checkpoint Inhibitors Sales Market Share by Type in 2016

Table Africa Immune Checkpoint Inhibitors Sales (K Pcs) by Application (2012-2017)

Table Africa Immune Checkpoint Inhibitors Sales Market Share by Application (2012-2017)

Figure Africa Immune Checkpoint Inhibitors Sales Market Share by Application (2012-2017)

Table Africa Immune Checkpoint Inhibitors Sales Volume (K Pcs) by Countries (2012-2017)

Table Africa Immune Checkpoint Inhibitors Sales Market Share by Countries (2012-2017)

Figure Africa Immune Checkpoint Inhibitors Sales Market Share by Countries (2012-2017)

Figure Africa Immune Checkpoint Inhibitors Sales Market Share by Countries in 2016

Table Africa Immune Checkpoint Inhibitors Revenue (Million USD) by Countries (2012-2017)

Table Africa Immune Checkpoint Inhibitors Revenue Market Share by Countries (2012-2017)

Figure Africa Immune Checkpoint Inhibitors Revenue Market Share by Countries (2012-2017)

Figure Africa Immune Checkpoint Inhibitors Revenue Market Share by Countries in 2016

Figure South Africa Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Nigeria Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Egypt Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Algeria Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Table Bristol Myer Squibb Immune Checkpoint Inhibitors Basic Information List

Table Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (K Pcs) and Growth



Rate (2012-2017)

Figure Bristol Myer Squibb Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure Bristol Myer Squibb Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table AstraZeneca Immune Checkpoint Inhibitors Basic Information List

Table AstraZeneca Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure AstraZeneca Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure AstraZeneca Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure AstraZeneca Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table Merck & Co. Immune Checkpoint Inhibitors Basic Information List

Table Merck & Co. Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Merck & Co. Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Merck & Co. Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure Merck & Co. Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table Roche / Genentech Immune Checkpoint Inhibitors Basic Information List

Table Roche / Genentech Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Roche / Genentech Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Roche / Genentech Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure Roche / Genentech Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table Incyte Corporation Immune Checkpoint Inhibitors Basic Information List

Table Incyte Corporation Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Incyte Corporation Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Incyte Corporation Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure Incyte Corporation Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table NewLink Genetics Immune Checkpoint Inhibitors Basic Information List

Table NewLink Genetics Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure NewLink Genetics Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure NewLink Genetics Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure NewLink Genetics Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table ArGEN-X Immune Checkpoint Inhibitors Basic Information List

Table ArGEN-X Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure ArGEN-X Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure ArGEN-X Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure ArGEN-X Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table Seattle Genetics Immune Checkpoint Inhibitors Basic Information List

Table Seattle Genetics Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Seattle Genetics Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Seattle Genetics Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure Seattle Genetics Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table Pfizer Immune Checkpoint Inhibitors Basic Information List

Table Pfizer Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Pfizer Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure Pfizer Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure Pfizer Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table MacroGenics Immune Checkpoint Inhibitors Basic Information List

Table MacroGenics Immune Checkpoint Inhibitors Sales (K Pcs), Revenue (Million

USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure MacroGenics Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate (2012-2017)

Figure MacroGenics Immune Checkpoint Inhibitors Sales Market Share in EMEA (2012-2017)

Figure MacroGenics Immune Checkpoint Inhibitors Revenue Market Share in EMEA (2012-2017)

Table Celldex Therapeutics Immune Checkpoint Inhibitors Basic Information List

Table CureTech Immune Checkpoint Inhibitors Basic Information List

Table Immutep Immune Checkpoint Inhibitors Basic Information List

Table Innate Pharma Immune Checkpoint Inhibitors Basic Information List

Table Sorrento Therapeutics Immune Checkpoint Inhibitors Basic Information List

Table GlaxoSmithKline Immune Checkpoint Inhibitors Basic Information List

Table GATR, Inc Immune Checkpoint Inhibitors Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Immune Checkpoint Inhibitors

Figure Manufacturing Process Analysis of Immune Checkpoint Inhibitors

Figure Immune Checkpoint Inhibitors Industrial Chain Analysis

Table Raw Materials Sources of Immune Checkpoint Inhibitors Major Manufacturers in 2016

Table Major Buyers of Immune Checkpoint Inhibitors

Table Distributors/Traders List

Figure EMEA Immune Checkpoint Inhibitors Sales (K Pcs) and Growth Rate Forecast (2017-2022)

Figure EMEA Immune Checkpoint Inhibitors Revenue and Growth Rate Forecast (2017-2022)

Figure EMEA Immune Checkpoint Inhibitors Price (USD/Pcs) and Trend Forecast (2017-2022)

Table EMEA Immune Checkpoint Inhibitors Sales (K Pcs) Forecast by Region (2017-2022)

Figure EMEA Immune Checkpoint Inhibitors Sales Market Share Forecast by Region (2017-2022)

Table EMEA Immune Checkpoint Inhibitors Revenue (Million USD) Forecast by Region (2017-2022)

Figure EMEA Immune Checkpoint Inhibitors Revenue Market Share Forecast by Region (2017-2022)

Table Europe Immune Checkpoint Inhibitors Sales (K Pcs) Forecast by Countries

(2017-2022)

Figure Europe Immune Checkpoint Inhibitors Sales Market Share Forecast by Countries (2017-2022)

Table Europe Immune Checkpoint Inhibitors Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Europe Immune Checkpoint Inhibitors Revenue Market Share Forecast by Countries (2017-2022)

Table Middle East Immune Checkpoint Inhibitors Sales (K Pcs) Forecast by Countries (2017-2022)

Figure Middle East Immune Checkpoint Inhibitors Sales Market Share Forecast by Countries (2017-2022)

Table Middle East Immune Checkpoint Inhibitors Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Middle East Immune Checkpoint Inhibitors Revenue Market Share Forecast by Countries (2017-2022)

Table Africa Immune Checkpoint Inhibitors Sales (K Pcs) Forecast by Countries (2017-2022)

Figure Africa Immune Checkpoint Inhibitors Sales Market Share Forecast by Countries (2017-2022)

Table Africa Immune Checkpoint Inhibitors Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Africa Immune Checkpoint Inhibitors Revenue Market Share Forecast by Countries (2017-2022)

Table EMEA Immune Checkpoint Inhibitors Sales (K Pcs) Forecast by Type (2017-2022)

Figure EMEA Immune Checkpoint Inhibitors Sales Market Share Forecast by Type (2017-2022)

Table EMEA Immune Checkpoint Inhibitors Sales (K Pcs) Forecast by Application (2017-2022)

Figure EMEA Immune Checkpoint Inhibitors Sales Market Share Forecast by Application (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

## I would like to order

Product name: EMEA (Europe, Middle East and Africa) Immune Checkpoint Inhibitors Market Report 2017

Product link: <https://marketpublishers.com/r/E6E04877476PEN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E6E04877476PEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

